ArticlePsychopharmacology2005
A parametric analysis of olanzapine-induced weight gain in female rats.
Article in Psychopharmacology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 126 citations in OpenAlex.
- A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers.PloS one · 2011Trial
- Longitudinal Gut Microbiota Dysbiosis Underlies Olanzapine-Induced Weight Gain.Microbiology spectrum · 2023Article
- Olanzapine decreased osteocyte maturation and Wnt/β-catenin signaling during loading of the alveolar bone in rats.Biomolecules & biomedicine · 2023Article
- Selective 5-HTPharmaceuticals (Basel, Switzerland) · 2023Article
- Crystal structures of non-oxidative decarboxylases reveal a new mechanism of action with a catalytic dyad and structural twists.Scientific reports · 2021Article
- Understanding the Effects of Antipsychotics on Appetite Control.Frontiers in nutrition · 2021Review
- Empagliflozin Effectively Attenuates Olanzapine-Induced Body Weight Gain in Female Wistar Rats.Frontiers in pharmacology · 2021Article
- Susceptibility of male wild type mouse strains to antipsychotic-induced weight gain.Physiology & behavior · 2020Article
- The Role of Adiponectin in the Pathogenesis of Metabolic Disturbances in Patients With Schizophrenia.Frontiers in psychiatry · 2020Review
- Preclinical and Clinical Sex Differences in Antipsychotic-Induced Metabolic Disturbances: A Narrative Review of Adiposity and Glucose Metabolism.Journal of psychiatry and brain science · 2019Article
- Macrophage migration inhibitory factor mediates metabolic dysfunction induced by atypical antipsychotic therapy.The Journal of clinical investigation · 2018Article
- Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects.Current neuropharmacology · 2018Review
- A Study to Assess the Therapeutic Effect of Enalapril on Olanzapine Induced Metabolic Syndrome in Wistar Rats.Journal of clinical and diagnostic research : JCDR · 2017Article
- Artesunate prevents rats from the clozapine-induced hepatic steatosis and elevation in plasma triglycerides.Neuropsychiatric disease and treatment · 2017Article
- The utility of behavioral economics in expanding the free-feed model of obesity.Behavioural processes · 2016Review
- Article
- Meal-induced insulin sensitization is preserved after acute olanzapine administration in female Sprague-Dawley rats.Naunyn-Schmiedeberg's archives of pharmacology · 2015Article
- Phosphorylation of hypothalamic AMPK on serine(485/491) related to sustained weight loss by alpha-lipoic acid in mice treated with olanzapine.Psychopharmacology · 2014Article
- Chronic treatment with olanzapine increases adiposity by changing fuel substrate and causes desensitization of the acute metabolic side effects.Naunyn-Schmiedeberg's archives of pharmacology · 2014Article
- Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleSome novel antipsychotics, including olanzapine, induce weight gain and metabolic abnormalities, which represent the major adverse effects of these drugs. However, the mechanism(s) involved in such effects are unclear.
objectiveThe aim of this study was to develop, in female rats, a parametric model of olanzapine-induced weight gain and metabolic abnormalities and evaluate it against clinical findings.
methodsFemale rats were administered olanzapine b.i.d. at doses of 0, 1, 2 and 4 mg/kg over 20 days, and a wide range of variables were recorded during and after drug administration.
resultsOlanzapine increased both 24 h and total food intake. This was associated with rapid onset weight gain and increased adiposity (assessed by visceral fat pad masses). Insulin, but not glucose, concentrations were elevated, with a significant increase in the HOMA-IR index, indicative of insulin resistance. A nonsignificant trend towards higher levels of leptin was observed. Paradoxically, there was a significant increase in adiponectin. All of these variables showed maximal increases at either 1 or 2 mg/kg and attenuated effects at 4 mg/kg. Prolactin levels were also increased by olanzapine. However, for this variable, there was a clear dose-response curve, with the maximal effect at the highest dose (4 mg/kg).
conclusionsThese data suggest that aspects of olanzapine-induced weight gain and metabolic abnormalities can possibly be modelled in female rats. It is suggested that olanzapine-induced hyperphagia acts as an initial stimulus which leads to weight gain, enhanced visceral adiposity and subsequent insulin resistance, although the latter may be ameliorated by compensatory responses in adiponectin levels. Prolactin elevation appears likely not to be involved in the weight gain, adiposity and metabolic changes seen in this model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.